Table 3.
High percentages of VAC057 donors, by matched HLA-DR allele, recall three RH5 class II clusters located in the N-terminal region of the protein.
| Peptide # | HLA Allele | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| DR1 | DR3 | DR4 | DR7 | DR8 | DR9 | DR11 | DR13 | DR15 | |
| 3 | 33% | 25% | 67% | 40% | ND | ND | 50% | 100% | 100% |
| 4 | 100% | 75% | 100% | 60% | ND | ND | 50% | 100% | 50% |
| 6A | 67% | 75% | 83% | 40% | ND | ND | 50% | 100% | 25% |
| N | 3 | 4 | 6 | 5 | 0 | 0 | 2 | 2 | 4 |
High percentages of ex vivo IFN-γ recall responses were confirmed to three RH5 class II clusters (clusters 3, 4, and 6 represented by 3 peptides) in the N-terminal region of RH5 using HLA-matched donors from the VAC057 clinical trial (ChAd63 RH5 vaccinees). The threshold positivity cut-off was ≥ 20 SFC/million PBMCs for media subtracted recall responses. Percentage of donors responding, by HLA allele for each peptide, is shown numerically along with color-coding to indicate higher percentages of responders with darker blues. The number of HLA-matched donors (N) for each allele is shown in the bottom row (14 donors total). Note that the number of HLA-matched donors was low for certain alleles and no HLA-matched donor PBMCs were available for DR8 and DR9. ND = not determined due to no HLA-matched donor PBMCs available.